Recent progress and considerations for AAV gene therapies targeting the central nervous system

Table 1 Known cellular receptors for different AAV serotypes

Serotype	Glycan recognition^a	Coreceptor
AAV1	Neu5Acα2-3GalNAcβ1-4GlcNAc	Unknown
AAV2	6-O- and N-sulfated heparin	Fibroblast [108]/hepatocyte [109] growth factor receptor; laminin receptor [110]; integrin αVβ5 [111] and α5β1 [112]
AAV3	2-O- and N-sulfated heparin	Hepatocyte growth factor receptor [113]; Laminin receptor [110]
AAV4	Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcNAcβ1-4GlcNAc	Unknown
AAV5	Neu5Acα2-3(6S)Galβ1-4GlcNAc	Platelet-derived growth factor receptor [114]
AAV6	Neu5Acα2-3GalNAcβ1-4GlcNAc; N-sulfated heparin	Epidermal growth factor receptor [115]
AAV7	Unknown	Unknown
AAV8	Unknown	Laminin receptor [110]
AAV9	Galactose [116]	Laminin receptor [110]

^aAll glycan recognitions listed, except for AAV9, are from a study by Mietzsch et al. [117] and are more specific glycans compared to the original publications identifying the primary glycans recognized by each serotype

ISSN: 1866-1955